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Abstract 
Background: Our previous results showed that intrasynovial Rifamycin SV caused the lysis of synoviocites and freed 
the autoantigens which in turn stimulated the immunoregulatory rather than autoreactive T cell response in rheuma-
toid patients. Here, we hypothesize that disruption in vitro of peripheral blood mononuclear cells, by freeze/thawing 
or by lytic action of Rifamycin SV, would induce the release of endosomal pathogenic autoantigens from APCs present 
in the circulation, which could then be isolated from degrading enzymes by ultrafiltration.
Methods: The preparation of the ultrafiltrates are based on the rupture of PBMCs (5 × 106 cells/mL) by the addition 
of Rifamycin SV in culture (250 μg/mL), which causes the lysis of 90 % of the cells in 3 h, or by three cycles of freeze/
thawing of the PBMC, from −80 °C to room temperature. The lysate and the fragmented cells were then centrifuged 
and ultrafiltered by passage through a filtration device with a cut-off of 10 kDa. Also the synovial fluid was subjected 
to ultrafiltration.
Results and conclusions: At clinical monitoring of the 30th day, 22/58 (38 %) patients subcutaneously treated with 
the autologous ultrafiltrate prepared by the freeze/thawing of PBMCs reached an ACR20. Comparable results were 
obtained with the other two ultrafiltrates.
Cell cultures The addition of ultrafiltrates to rheumatoid PBMCs cultures led to the upregulation of a marker for T-reg-
ulatory cells, and downregulation of a cell proliferation marker; changes that together have the meaning of a global 
immunomodulatory response and that only a specific antigen (ultrafiltrate UF-f/t) might induce in the rheumatoid 
patient, probably by activating pre-existing protective network.
Experimental arthritis All the ultrafiltrates except that prepared by Rifamycin SV were able to modulate the adjuvant 
arthritis in rats. In particular, longlasting synovial fluid induced a significant reduction of the severity of subsequent 
arthritis (p < 0.01) while SF from recent RA effusion (5–10 days after a previous complete extraction) and knee 
osteoarthrosis were ineffective. It is reasonable to assume there are at least two unknown endosomal immunoactive 
epitopes; one developing its immunotherapeutic property in RA, and the other, related to the molecule of HSP60, 
reduces the severity of oncoming arthritis. Both epitopes are present in humans, have a molecular weight of ≤10 kDa 
and do not appear to be bystander antigens. Please see Additional file 1 for the abstract in Italian.
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Background
Rifamycin SV is an old antibiotic endowed with a cyto-
lytic property that completely lyses synovial cells and 
most likely frees the autoantigen anchored on the bind-
ing groove of antigen presenting cells (APCs) [1, 2]. Rifa-
mycin SV also provokes the release of all short proteins at 
various stages of enzymatic degradation from the endo-
somal compartment. The good therapeutic response to 
Rifamycin SV injected into the arthritic knee [3–7] and, 
in particular, the systemic effects obtained when the 
application is extended to many joints [8–10] have led 
us to hypothesize that this antibiotic, once infiltrated in 
joints, frees the pathogenic peptide from synovial APCs, 
which, in conjunction with MHC class II molecules, 
would otherwise present this peptide to autoreactive T 
cell receptors, contributing to the continued immune 
response. The peptide itself might then instead favor an 
interaction with the antigen-binding site of an anti-idio-
type T-cell (paratope) [11, 12], activating an immunoreg-
ulatory response.
The idiotype-anti-idiotype network on membrane 
is considered central in immunoregulation involving 
autoantigens [13].
The use of a specific autoantigen at appropriate doses to 
bypass interaction with autoreactive T lymphocytes and 
thus detrimental immune response has been shown to 
cure spontaneous autoimmune disease, as with glutamic 
acid decarboxylate (GAD 65) in the non-obese diabetic 
rat [14]. Thus, the isolation and identification of autoanti-
gens for other autoimmune disorders such as rheumatoid 
arthritis (RA) might have considerable therapeutic ben-
efit. To facilitate this, the use of peripheral blood mono-
nuclear cells (PMBCs) of subjects with RA as a source to 
extract the pathogenic peptides in vitro instead of the less 
accessible synovial cells has been considered.
This is based on the notion that, although very differ-
ent in number, many peripheral blood cells including 
macrophages, dendritic cells, and B lymphocytes, possess 
functional characteristics that are commonly attributed 
to actual APCs [15, 16]. All potential APCs are capable of 
degrading the antigens in their endosomal compartment; 
the subsequent transfer of the resultant peptides to the 
cell surface and their presentation to lymphocytes gives 
rise to immunoinflammation [17].
Within PBMCs, research on the pathogenesis of sys-
temic and organ-specific autoimmune diseases has 
expanded the complex role of B cells from the synthesis 
of antibodies and pro-inflammatory cytokines to that of 
internalization and presentation of antigens [18, 19].
B cells process and present the antigen peptides 
to CD4+ T lymphocytes in the context of MHC 
class II alleles. It has been argued that in established 
autoinflammatory conditions B cells represent a potent 
reservoir of APCs for activating T cells [20].
Starting from these considerations, we thought of 
inducing the release of pathogenic peptides from PBMCs 
in  vitro by causing the lysis or fragmentation of cells 
through the use of Rifamycin SV as a cytolytic sub-
stance, or through freeze/thawing of cells, respectively. 
Separation of unknown PBMC substances in the tube 
could determine the leak of autoantigen as well as all the 
intracellular material in which there are many unknown 
substances.
The separation of peptides and any other substances 
from lysates and from the suspension of cell fragments 
could be obtained by centrifugation and subsequent 
immediate ultrafiltration (mw ≤10  kDa). All the mol-
ecules of low weight could be collected in the flow-
through. Among these, in addition to the short proteins 
from the endosomal compartment, might be included 
the specific arthritogenic peptides.
The same method of separation could be applied to 
rheumatoid synovial fluid as well. In the context of syn-
ovitis, the release of pathogenic peptides is induced by 
inflammatory disruption of the synovial cells. The imme-
diate ultrafiltration of centrifuged fluid would allow 
immunoactive peptides, free of molecules involved in 
the endosomal processing of antigens (e.g., class II-asso-
ciated invariant peptide) and not linked to the molecule 
HLA DR, to be collected in the flow-through.
As first step in determining the identity of the 
autoantigen(s) in RA, in this study, we have prepared four 
ultrafiltrates, two of which were derived from the break-
down of PBMCs, one from the supernatant of PBMCs 
cultures and one from synovial fluid.
Three of these were utilized in trials of autologous 
immunotherapy by injecting them subcutaneously in 
patients with early RA (disease duration of less than 
12  months) and for a protection protocol in adjuvant 
arthritis (AA) in rats (iv administration 7, 8 days after AA 
induction). We chose AA model because is considered a 
disease mediated by auto reactive T cells cross-reacting 
with mycobacterial hsp65 [21, 22], which is a stress pro-
tein highly conserved through the evolution, from bac-
teria to man, and yet the arthritogenic autoantigen(s) 
remains elusive [23].
Methods
Preparation of ultrafiltrates
All procedures were performed in BSL3. The ultrafiltrate 
preparation protocol was performed using sterile equip-
ment in laminar flow cabinet with HEPA filter. The ste-
rility of PBMC ultrafiltrates was tested by placing it in 
culture on Blood Agar and Muller Hinton broth.
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Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells were isolated from 
whole blood using Histopaque-1077 polysucrose and 
sodium diatrizoate solution, according to manufacturer’s 
instructions
Briefly, whole blood samples from the patients were 
labeled with a univocal barcode defined by the protocol 
and diluted 1:2 with 1× PBS in a labeled 50-mL Falcon 
tube. In a second Falcon tube, 10 mL of Histopaque-1077 
was added, onto which 20 mL of diluted blood was sub-
sequently layered. Then, Falcon tubes were centrifuged 
at 750×g for 30 min at room temperature, without brake 
deceleration. The PBMCs were then collected, divided 
into four 15-mL Falcon tubes, and centrifuged three 
times at 650×g for 10  min, at room temperature, in 
10 mL of 1× PBS solution to remove the red blood cells. 
Finally, PMBCs were counted and stored at −80 °C, at a 
final concentration of 5 × 106 cells/mL, in tubes labeled 
with the appropriate protocol barcode.
Ultrafiltrate UF‑S (mononuclear cell supernatant)
PBMCs (5 × 106 cells/mL) were cultured in shell vials in 
RPMI 1640 medium containing 20 % fetal calf serum, at 
37 °C, in a 5 % CO2-enriched atmosphere for 3 h. At the 
end of the incubation period, the supernatant was col-
lected after centrifugation at 350×g for 10 min, ultrafil-
trated by passage through a Millipore filtration device 
with a molecular weight cut-off value (MWCO) of 
10,000  kDa (Millipore Corporation, Bedford, USA), and 
stored at −20° until use.
Ultrafiltrate UF‑R
For the preparation of ultrafiltrate for use in immuno-
therapy, rifamycin SV, stored in 10-mL (250  mg) vials 
(Lepetit Spa, Milan) (for intravenous use), was utilized.
PBMCs (5  ×  106 cells/mL) were cultured under the 
same conditions, but in the presence of 250  μg/mL of 
rifamycin SV, for 3 h. At the end of the incubation period, 
the rate of cell lysis observed was 90 %. The supernatant 
was collected after centrifugation at 350×g for 10  min 
and the ultrafiltrate was prepared as described above. The 
flow-through was used within 2–3 days, and the remain-
der was stored at −20 °C. The ultrafiltrate prepared with 
rifamycin SV was used in clinical trials.
Ultra filtrates UF‑f/t
PBMCs were purified using Histopaque-1077, as 
described above, but cell lysis was not performed.
Briefly, PBMCs were subjected to three freeze/thaw 
cycles from −80  °C to room temperature and centri-
fuged at 1500×g for 10 min; up to 1.5 mL of sample was 
then transferred into Millipore filtration devices with a 
MWCO of 10,000  kDa, and centrifuged at 1500×g for 
10  min in labeled 50-mL Falcon tubes. The ultrafiltrate 
was collected in 2 mL tubes and stored at −20 °C.
It should be noted that epitopes bound to HLA-DR 
(>10 kDa) are too large to pass through the pores of the 
ultrafilter while the free pathogenic epitope and other 
endosomal peptide easily pass.
Generally, the ultrafiltrate was prepared a few days 
before its subcutaneous administration. A portion of the 
ultrafiltrate was stored separately for in vitro studies (see 
below).
Ultrafiltrate UF‑sf
Synovial fluid from a long-lasting (for at least a month) 
inflammatory effusions, was centrifuged to remove the 
cells and then subjected to ultrafiltration using the proce-
dures described above. The ultrafiltrate was used within 
2 days, and the remainder was stored as above.
Rheumatoid arthritis
Patients
Patients recruited for this study fulfilled the American 
College of Rheumatology (ACR) 1987 revised criteria for 
RA [24]; specifically, patients with disease duration of less 
than 1 year and who had not been previously treated with 
immunosuppressive agent were recruited. The inclusion 
criteria were as follow: age between 17 and 75 years, ACR 
functional class I, II or III [25], presence of active disease 
symptoms such as nine or more tender joints at rest or in 
motion, six or more swollen joints, a pain score of greater 
than four on the Visual Analog Scale (VAS) and an eryth-
rosedimentation rate (ESR) of >30 mm/h. The exclusion 
criteria were as follow: known allergy to Rifamycin SV 
antibiotic, a positive intra-dermal sensitivity test for Rifa-
mycin SV, the intra-articular or parenteral administration 
of corticosteroids 4 weeks prior to the study.
Study design and monitoring
In this study, three of four ultrafiltrate samples, which 
were prepared as described above, were used: UF-sf 
(prepared from rheumatoid acellular synovial fluid), UF-
f/t (prepared by freeze/thawing of PBMCs), and UF-R 
(obtained by lysing mononuclear cells from patients 
using Rifamycin SV).
The objectives of this study were to investigate the 
efficacy of autologous ultrafiltrates, administered via 
subcutaneous injection at baseline on two consecutive 
days, and to compare the response rate on the 10th day 
vs those on the 30th day in each of the three treatment 
groups.
AS the groups were not homogeneous in terms of 
patient characteristics the response rates of the different 
groups to treatment could not be compared, therefore 
the groups were evaluated separately.
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The choice of non-placebo group was based on ethi-
cal, practical and methodological considerations. Moreo-
ver, a single blind study design, in which the investigator 
evaluating the response was not aware of the treatment 
administered, ensured the absence of assessment bias.
The study design included randomization between 
groups; however after the first ten randomized patients 
70 % of patients tested positive for intra-dermal sensitiv-
ity test to Rifamycin SV (wheal diameter ≥0.5 cm). This 
unexpectedly high percentage of patients sensitive to 
Rifamycin SV necessitated a change in the design of the 
study, in that the randomization procedure was no longer 
considered feasible.
The study design was modified according to the fol-
lowing criteria: patients (a) with a previous or current 
history of allergic or autoimmune diseases other than 
RA, such as atopic dermatitis, chronic hypersensitiv-
ity pneumonitis, leukopenia due to hypersensitivity, and 
asthma, (b) with clinical conditions that may be aggra-
vated by Rifamycin SV such as elevation of liver enzymes, 
impaired creatinine clearance, cholelithiasis, (c) who may 
have been treated with the Rifamycin SV (e.g., patients 
with previous tubercular infection) and those who were 
treated with this antibiotic via the intrasynovial route for 
arthritis, and (d) nurses were excluded from the UF-R 
group and included in the UF-f/t group. In addition, 
only patients presenting synovial effusion of knees were 
included in the UF-sf group.
A total of 115 patients with active RA were enrolled in 
this study at the L. Sacco Hospital, 11 of whom had joint 
effusions of both knees. Patients in groups UF-R and UF-
f/t were administered the previously prepared ultrafil-
trate (1.7–2 mL) at subcutaneous sites on the forearm on 
two consecutive days, whereas those in the UF-sf group 
received 0.8–2  mL of ultrafiltrate upon availability. An 
adverse reaction to these antigens was unlikely as periph-
eral lymphocytes reactive to self peptides are eliminated 
during ontogeny via negative selection.
The study design was approved by the Ethics Commit-
tee of L. Sacco Hospital and by the Ethics Committee of 
the Regional Government of Lombardia, Italy (Resolu-
tion number 599 of July 30 2009). Informed consent was 
obtained from all patients. Patients underwent a com-
plete physical assessment and 30–50 mL peripheral blood 
was drawn for blood tests and cell ultrafiltrate prepara-
tions and synovial fluid, where present, was completely 
drained. The following were evaluated for measurement 
of changes from the baseline at every assessment: swollen 
joint count, tender joint count, pain score (VAS), patient 
and physician global assessment of disease activity (VAS), 
and efficacy according to the ACR criteria [26]. Inspec-
tion of the injection site and general tolerability were 
evaluated at the 10th and 30th  day of the clinical trial. 
An immune response to a subcutaneous administra-
tion of any antigen rarely lasted for more prolonged than 
30 days. However, more detailed studies are necessary to 
define the schema of this immunotherapy.
Rheumatoid arthritis—in vitro studies
Cells and ultrafiltrate
The cells for the cultures were obtained from a pool of 
about 50 mL whole blood, drawn from six patients with 
active rheumatoid disease. The cells, purified on His-
topaque-1077 were frozen at 5–10  ×  106 cells/mL and 
stored in a cryogen tank until use. At the time of use, the 
PBMCs were thawed and centrifuged at 750g for 10 min, 
washed 3× with PBS, and resuspended at 0.5–2  ×  106 
cells/mL DPBS (Dulbecco’s Phosphate-Buffered Saline. 
Carlo Erba. C Dasit group. Milan).
Cells were grown in RPMI1 1640 supplemented with 
10 % heat inactivated human AB serum, 100 U/mL peni-
cillin, 100  μg streptomycin, and 1  mM glutamine. The 
PBMCs were cultured at 0.5–2 × 106 per well in a 48 well 
plate for 48 h with media alone, or stimulated with plas-
tic bound anti-CD3 (clone OKT3) (5 μg/mL) and soluble 
anti-CD28 (2  μg/mL), 10  μg/mL tetanus toxoid-derived 
peptide (QYIKANSKFIGITE) or hsp60 (GEALSTLV-
VNKIRGT) (Becton–Dickinson). Cultures were set up in 
duplicate with one set receiving 400 μL (0.1 mg protein 
per well) of UF-sf. The PBMC ultrafiltrate was adjusted to 
10 % human AB serum prior to addition to cell cultures. 
After 48 h, the cells were harvested and immunostained 
as described below. The UF-sf for the in  vitro studies 
were the same as those prepared and employed as autolo-
gous vaccines.
Ultrafiltrates
For UF-sf, the samples stored at −20 °C were thawed and 
pooled in the laboratory for in vitro assays. A micro BCA 
protein assay (Pierce Biotecnology, Rockford, IL) was 
performed to determine the protein concentration of the 
pooled ultrafiltrates. The ultrafiltrate prepared with Rifa-
mycin SV was excluded from this study because it can-
not be removed from the extract, making in vitro studies 
difficult.
SDS‑PAGE and western blot analysis
Several experiments were performed to attempt to visu-
alize the protein of interest on a gel. These experiments 
were performed with some of the patient samples as well 
as with samples from donors recruited for this purpose. 
The ultrafiltrates prepared with Rifamycin SV were run 
on 4–12 % SDS-PAGE gels and silver staining and west-
ern blot analysis with anti-hsp60 (Becton–Dickinson, San 
Diego, CA), as the detection antibody, were used for pro-
tein visualization.
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FACS analysis
Cell staining was used to measure (1) TNF-alpha produc-
tion by T cells and macrophages, (2) CD69 as an indica-
tor of cell proliferation and (3) CTLA-4 expression by 
CD4+/CD25+ cells as an inhibitor of T cell function. 
Isotype controls were included to determine non-specific 
antibody staining. Monensin was added to the PBMC 
cultures 4 h prior to immunostaining, and the cells were 
harvested and extracellular immunostaining was per-
formed with antibodies to human CD3 (clone UCHT1), 
CD4, CD25, CD69 and CD11 (Becton–Dickinson). The 
cells were fixed with paraformaldehyde and intracellular 
staining was performed with antibodies to TNF-alpha 
and CTLA-4 in the presence of saponin. Appropriate iso-
type controls were also included.
Ultrafiltrate from a normal donor is not toxic to normal 
BPMCs
In order to test the possible toxicity of ultrafiltrate on 
cells and to determine the appropriate volume to use for 
subsequent patient studies, the effects of normal donor 
ultrafiltrate on CD69 expression, a marker for cell prolif-
eration, by T cells in cultures with normal PBMCs, were 
evaluated. PBMCs were cultured with increasing volumes 
of UF-f/t (from 0 to 500 μL) in the presence or absence 
of anti-human CD3 (5 μg/mL) and CD28 (2 µmL). Cells 
were incubated for 24 or 48 h and co-stained with anti-
CD3 and anti-human CD69. The proliferation of stimu-
lated cells, as measured by the expression of CD69, (% 
CD69/CD3), was consistently high with all volumes of 
ultrafiltrate.
Not being toxic the maximum feasible amount of ultra-
filtrates (400 µ) were used. Additionally, CD69 expression 
was higher at 48 h and that cultures time was used (the 
tables are available on request).
Adjuvant arthritis in rats
Animals studies were performed at the LITA laboratories, 
Microbiology Chair, University of Milano (Italy)
Induction and assessment of arthritis Adjuvant arthritis 
(AA) was induced by intracutaneous injection of 0.1 mL of 
paraffin oil containing 10 mg/mL of heat-killed Mycobac‑
terium butirricum, into the base of the tail of female Lewis 
rats. Active disease developed 11–12 days after injection 
reaching a peak at 17–21 days; this was followed by slow 
resolution. Severity of arthritis was evaluated every fourth 
day by the measurement of clinical signs in each paw, on 
a scale of 0–2. The maximum arthritis score was eight per 
animal. The rats lost 5  % of their body weight over the 
course of the clinical disease.
Protection protocol using ultrafiltrates Fifty rats were 
randomized into the following five treatment groups: 
Rifamycin SV alone (250  μg/mL), saline solution, UF-S, 
UF-f/t or UF-R, and intravenously treated, with 0.5 mL/
rat/day, on days 7 and 8 after AA induction. We did not 
administer ultrafiltrate during the overt manifestation of 
arthritis.
Collection of synovial fluid Synovial fluids were obtained 
from eight patients with rheumatoid arthritis with long-
lasting knee effusions, six with recent effusions (5–10 days 
after a previous complete extraction) and six with arthro-
sis. Synovial fluids were centrifugated at 400×g for 15 min; 
the supernatant was the ultrafiltrated as above and stored 
at −20 °C until use.
Protection protocol using ultra filtrate UF‑sf Animals 
(n = 8) were injected in the tail vein with 0.5 mL of UF-sf 
or saline solution (control) (8). Each animal was treated 
with UF-sf obtained from an individual patient. Twenty-
one days after AA induction the arthritis severity was 
scored by grading each hind paw.
Statistical analysis
In vitro studies
Changes from the 10th to the 30th  day were assessed 
using a Chi square test for the UF-f/t and UF-R groups 
using 95  % confidence intervals, whereas the Fisher’s 
exact test was used for the third comparison with the 
UF-sf group, because of the low number of patients 
therein. For immunohistochemistry, nonspecific staining 
as determined with the isotype controls was subtracted 
(as percentage) from the positive responses. Differences 
between matched untreated PBMCs and samples treated 
with ultrafiltrates were analyzed by the Wilcoxon paired 
rank test.
Clinical studies
All data concerning the protective protocol in rats were 
analysed with non-parametric tests. To compare the dif-
ferent groups, the Friedman’s test was performed with 
time and treatment as variables. Synovial fluid results 
were analysed by one way analysis of variance followed 
by Bonferroni T test for multiple comparisons.
Results and discussion
Rheumatoid arthritis
The results reported in Table 1 show that the three autol-
ogous ultrafiltrates, administered subcutaneously, led to 
good therapeutic effects. In some patients, these effects 
occurred early, sometimes after just a week, and lasted 
at least until the final check of the 30th day. In the UF-R 
group, 37  % (17/46) of the patients achieved an ACR20 
by the 10th  day vs 33  % (19/58) of those receiving UF-
f/t. The patients who received UF-sf showed a still higher 
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ACR20 response rate of 64  % (7/11). In the subsequent 
20  days, the number of patients with a positive thera-
peutic response increased slightly in UF-R and UF-f/t, 
from 17 to 19 (41  %) and 19 to 22 (38  %), respectively, 
and the final results were comparable between these 
groups. In contrast, patients in the UF-sf group remained 
unchanged (64 %). The comparison of the results between 
the 10th and the 30th  day did not show any significant 
difference in any of the three groups.
Among the three ultrafiltrates, UF-f/t would appear to 
be preferred for clinical use although its response rate by 
the 30th day was the lowest (22/58, 38 %), because it is 
the easiest to prepare and can be prepared and admin-
istered the same morning. On the other hand, UF-R has 
the disadvantage of potential patient hypersensitivity 
reaction to the antibiotic, Rifamycin SV, which cannot 
be eliminated from the PBMC lysates (see safety). It has 
been reported that serious side effects occur in patients 
who take the Rifamycin SV intermittently [27]. Finally, 
UF-sf presents the greatest obstacle for practical use 
because only a minority of patients have abundant syno-
vial fluid in their knees.
Rheumatoid arthritis in vitro studies
As previously suggested, we expect that the immune-
active epitope should be the same between the three 
ultrafiltrates. Therefore, for the in  vitro studies, we 
employed the ultrafiltrates UF-f/t and UF-sf but not 
UF-R, as it was prepared with Rifamycin SV.
Notably, in the latter the Rifamycin SV itself was the 
only low molecular weight protein detected (SDS-PAGE), 
which might have interfered with the detection of other 
small molecular weight proteins. The Western blots also 
showed no proteins when an anti-heat shock protein 
antibody was used for detection.
Immunomodulatory activity of ultrafiltrates on PBMCs 
from patients with RA
For this study we chose to test the ultrafiltrate UF-sf 
because the concentration of the pathogenic epitope in syn-
ovial fluid could be greater than in the ultrafiltrate UF-f/t.
This we have deduced from experiment reported in 
Table  4 (see below) in which longlasting synovial fluid 
was significantly more effective than the recent one in the 
inhibitory activity against AA showing the ability of the 
pathogenic epitope to accumulate.
PBMCs (1 × 106 per well) patients with active RA (6) 
were cultured in duplicate with UF-sf and stimulated 
with anti-CD3/CD28. After 48 h, the cells were harvested 
and immunostained for CD4/CD25, CTLA-4, CD69, 
CD11c and TNF-alpha. Very little TNF-alpha expres-
sion resulting from any of the treatments (peptides) was 
identified. Only anti-CD3 and CD28 stimulated the cells 
to proliferate and this proliferation as measured by CD69 
was significantly decreased by the addition of ultrafil-
trate (p = 0.04) (Fig. 1). CTLA-4 expression (a marker of 
T regulatory cells) by the same cell population increased 
slightly (not shown) despite the decrease in CD69 expres-
sion and was significant in the case of CD4+CD25+ T 
cells (p = 0.05) (Fig. 2). For background correction, non-
specific staining as determined using the isotype con-
trols, was subtracted from the positive responses.
Immunological response to autologous PBMC ultrafiltrates 
in patients with RA previously vaccinated (30 days) 
with autologous UF‑f/t
PBMCs from one normal subject and three patients 
with early RA who had been previously vaccinated, i.e., 
subcutaneously treated with autologous UF-f/t, were 
Table 1 Disease activity score after subcutaneous injection of autologous ultrafiltrates in early rheumatoid patients
a One subcutaneous administration in two consecutive days. For doses, see text
b American College Rheumatology criteria ≥20° relative risks (RR), calculated using Chi square Pearson test
Ultrafiltratesa Pts ACR ≥ 20b (10th day) vs (30th day) RR° 95 % CI p value
(%pts10th day) (%pts 30th day)
UF-R rifamycin SV (from 5 × 106 cells/mL) 46 17 (37) 19 (41) 0.90 0.54 1.49 NS
Ul-f/t freeze/taw (from 5 × 106 cells/mL) 58 19 (33) 22 (38) 0.86 0.53 1.42 NS
UF-sf (from acellular sin. fluid) 11 7 (64) 7 (64) 1 0.53 1.88 –
Fig. 1 Expression of CD69 by CD4+CD25+ cells from six RA patients. 
Results are shown as the mean and standard deviation of the six 
patients. Only anti-CD3 and CD28 stimulate the cells to prolifer-
ate and this proliferation as measured by CD69 was significantly 
decreased by the addition of lysate
Page 7 of 12Caruso et al. J Transl Med  (2016) 14:162 
cultured with the same autologous ultrafiltrate and then 
immunostained. When the Wilcoxon paired samples test 
was used to determine the differences between no treat-
ment and subcutaneously treatment with autologous 
ultra filtrates, no statistically significant differences were 
observed for any of the markers studied (Table 2). How-
ever, when CTLA-4 expression by CD4+CD25+ T-cells 
was examined, the addition of ultrafiltrate decreased the 
level of this marker in normal donors (−33  %), which 
appeared to correlate with the decrease in CD69+ 
expression. The opposite effect was observed in the 
autologous vaccinated patients with RA, who exhibited 
a decrease in CD69+ by CD4+CD25+ T cells but no 
change in CTLA-4 expression by the same cells follow-
ing the addition of ultrafiltrate. In addition, there was lit-
tle TNF-alpha production by either T cells or monocytes/
macrophages.
Synthesis
(a) The addition of UF-sf to PBMCs cultured from non-
vaccinated patients with RA (6) elicited significant 
reduction of CD69 by CD4+ cells (p = 0.04) and at 
the same time an increase of CTLA-4 expression by 
CD4+CD25+ cells (p = 0.05).
(b) The addition of autologous UF-f/t to PBMCs cul-
tured from vaccinated patients elicited minimal 
change in cellular markers.
(c) The addition of autologous UF-f/t decreased the 
expression of both CD69 (−25  %) and CTLA-4 
(−33 %) in normal subjects.
(d) The addition of antigen p1 (HSP65) did not show 
any response.
(e) Addition of the ultrafiltrate did not elicit a pro 
inflammatory response in any of the studied sub-
jects: normal donor, patients with RA, or patients 
with RA previously vaccinated with autologous 
PBMC ultrafiltrate.
Adjuvant arthritis
Table  3 reports the clinical scores of AA. Prevention of 
paw swelling after treatment with UF-S and UF-f/t was 
statistically significant (p < 0.01) compared with the con-
trol groups. These results showed that active unknown 
epitopes would be released in UF-S even during 3  h of 
culture (in the absence of Rifamycin), following a par-
tial spontaneous cytolysis. On the contrary, AA was not 
inhibited in rats treated with UF-R and Rifamycin alone 
(Table 3) and also by the UF-sf from patients with arthro-
sis (Table 4). Arthrosis is commonly accepted as the nor-
mal control for RA. 
The administration of long-lasting (more than a 
month) RA synovial fluid, UF-sf, induced a significant 
reduction of the severity of subsequent arthritis in rats 
(p < 0.01) while SF from recent RA effusion (5–10 days 
after a previous complete extraction) was ineffective 
(Table 4). The ineffectiveness of the recent fluid is prob-
ably due to the gradual accumulation over time of immu-
noactive epitopes from lysis of proliferating synoviocites 
and deeper mononuclear cells in inflamed synovium. The 
control saline treated animals had a severe arthritis, as 
demonstrated by the high clinical scores (Table 4).
In conclusion, longstanding synovial fluid, UF-sf, the 
supernatant of PBMC cultures, UF-S, and Ultrafiltrate 
of PBMCs fragmented with freeze/thawing, UF-f/t, all 
from subjects with RA, are able to modulate the immune 
mechanism implicated in AA and to stimulate protective 
immunity.
In Table  5, we summarize the results of autologous 
immunotherapy in RA patients and the protection pro-
file of the human ultrafiltrates administered in rats with 
oncoming arthritis.
Our strategy to extract and identify pathogenic 
epitopes was linked to the notion that in a systemic dis-
ease such as RA, the epitope would be present in the 
Fig. 2 Expression of CTLA-4 by CD4+CD25+ cells from six RA 
patients. Results are shown as the mean and standard deviation of six 
patients. CTLA-4 by the same cell population increase slightly despite 
the decrease in CD69 expression (not shown) and was significant in 
the case of the CD4+CD25+ T cells
Table 2 The effects of  autologous ultrafiltrate on  CD69 
and  CTLA-4 expression by  PBMCs stimulated with  CD3/
CD28
The results are shown as the untreated cells minus cells plus lysate. CD69 and 
CTLA-4 were down-regulated in the normal donor
Donor % CD69+/
CD4+
% CD69+/
CD4+CD25+
% CTLA‑ 
4+/CD4+
% CTLA‑4+/
CD4+CD25+
Normal 
(n = 1)
−25 −18 +4 −33
Patients 
(n = 3)
−7 −15 +4 +3
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APCs of PBMCs as well as in synovial cells. Recently, 
the presence of pathogenic-like T cells has been demon-
strated in the blood stream of adult forms of autoimmune 
arthritis and juvenile chronic arthritis; these T cells share 
genotypic and phenotypic characteristics with synovial T 
cells [28]. Thus, the presence of pathogenic lymphocytes 
implies the presence of APCs as well.
The ultrafiltration of lysate and/or the suspension of 
cellular fragments immediately after centrifugation were 
intended to retain the proteolytic enzymes and allow 
numerous unknown small molecules, including the pos-
sible autoantigen, to pass into the ultrafiltrate aqueous 
solution that was used for subcutaneous injection. This 
extremely simplistic theory is supported by the devel-
opment of an indisputable efficacy of the ultrafiltrates 
in patients with arthritis. Most notably, the therapeutic 
effect lasting 30 days from a subcutaneous dose is a type 
of response that differs completely from all known anti-
arthritic therapies [29].
In comparison, the administration of a specific, known 
autoantigen in appropriate doses, such as glutamic acid 
decarboxylate (GAD 65) in the non-obese diabetic rat, a 
well-known animal model of spontaneous autoimmune 
disease, has been shown to cure the disease [14].
In the present study, the two immunotherapeutic vac-
cines prepared from the rheumatoid PBMCs, UF-f/t and 
UF-R, reached different outcomes in the two diseases; 
the UF-R was unable to modulate the animal model of 
arthritis but was effective in patients with RA while the 
UF-f/t worked both in AA of rats, reducing the severity 
of oncoming arthritis, and in patients with RA leading to 
an improvement of arthritic symptoms (Tables 1, 5).
The other two ultrafiltrates, UF-S and UF-sf, exhib-
ited immunotherapeutic activities comparable to that of 
Table 3 Modulation of  adjuvant arthritis development in  rats by  administration of  ultrafiltrates obtained from  PBMCs 
of RA patients
Ten rats per group were injected with 0.5 µg/mL of each ultrafiltrate or 0.5 mL of Rifamycin SV (250 µmL) or saline solution at 7 and 8 days after arthritis induction
AA adjuvant arthritis, AI arthritis induction, RA rheumatoid arthritis
** p < 0.05 vs saline solution
Days from AI UF‑S** UF‑f/t** UF‑R Rifamycin Saline sol.
AA score Median AA score Median AA score Median AA score Median AA score Median
11 00000
00233
0 00000
11246
0.5 00122
22223
2 00001
11222
1 00011
22245
1.5
15 00012
24457
2 02222
33357
2.5 12223
33344
3 02333
33444
3 24445
55666
3
19 11244
45588
4 02344
45557
4 24555
66788
5.5 25555
66788
5.5 46666
67777
5.5
23 13333
55788
4 03344
55567
4.5 24555
66888
5.5 33344
56668
4.5 45555
66678
4.5
27 12223
36778
3 02344
44457
4 23455
55888
5 33334
55668
4.5 44445
55668
4.5
Table 4 Protection of  rats from  adjuvant arthritis 
by administration of synovial fluid (UF-sf)
Clinical score at 21 days after arthritis induction
RA rheumatoid arthritis, OA arthrosis
º p < 0.01 vs saline solution
a After a previous complete extraction
^Not significant. Each rat was treated with synovial fluid of an individual patient
Longlasting RA 
synovial fluid 
(N = 8)
Recent RA 
synovial fluid 
5–10 days 
(N = 6)a
OA synovial  
fluid (N = 6)
Saline solution 
(N = 8)
2.37 ± 1.60º 5.9 ± 1.01^ 6.7 ± 095^ 7.5 ± 0.92^
Table 5 Autologous immunotherapy of  RA with  ultrafiltrates derived from  PBMCs and  synovial fluids. The protection 
profile in AA is included
RA rheumatoid arthritis, AA adjuvant arthritis in rats, ND not done
Lysate ultrafiltrates Abbreviation RA patients autologously injected Adjuvant arthritis (AA) in rats iv injected
Prepared from acellular synovial fluid UF-sf Active Active
Prepared by freeze/thawing of PBMCs UF-f/t Active Active
Prepared from supernatant of PBMCs culture UF-S ND Active
Prepared by lysing PBMCs with rifamycin SV UF-R Active Ineffective
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the ultrafiltrate prepared by freeze/thawing of PBMCs 
(Table 5).
It is reasonable to assume that there are at least two 
unknown immunoactive epitopes, in both mononuclear 
cells and synovial fluid ultrafiltrates.
These epitopes are thrown out of disrupted cells, spe-
cially from their endosomal compartment, during the 
preparation of ultrafiltrates. They are not joined to any 
HLA DR molecule, they pass through an ultrafilter with 
a cut off of 10 kDa (see “Methods” section) and are free 
of molecules involved in the endocytic processing of anti-
gens (e.g., class II-associated invariant peptide).
The Rifamycin SV might have tied the epitope effec-
tive in AA, while preparing ultrafiltrate UF-R, but leav-
ing intact the epitope effective in human arthritis. This 
results in the disabling of its property to protect rats from 
experimental arthritis.
The epitopes (two or more) of synovial fluid, spon-
taneously released following the lysis of proliferating 
synoviocites and deeper mononuclear cell of inflamed 
synovium, accumulate over time. If drawn out again, just 
a few days after a complete extraction of the effusion, this 
rheumatoid synovial fluid was ineffective on prevention 
of AA, unlike longlasting synovial fluid (Tables 4, 5). This 
might explain the previous reports on depressed prolif-
erative response by PBMCs to mHsp60 in early RA [30]. 
The synovial fluids from arthrosis patients with arthro-
sis were always ineffective in modulating the AA of rats 
because they do not contain arthritogenic epitopes.
We know very little about the epitope effective in RA 
patients. It is present in both ultra filtrates of PBMCs 
and synovial fluid; it is effective as immunotherapeu-
tic approach and exhibits immunomodulatory activities 
when is added to rheumatoid cell cultures (see below). 
We do not know the amino acid structure and the precise 
molecular weight. But It is just as small, much smaller 
than those identified with the pan-DR-binding Hsp-
derived epitopes [31], as candidate for antigen specific 
bystander immunotherapy [32–35].
Once subcutaneously injected in RA patients, the 
epitope is transported by dendritic cells in inflammatory 
sites.
The status of the auto antigen in the ultrafiltrate, i.e., 
a peptidic fragment, not associated with a class II MHC 
molecule, might assist in explaining the early appearance 
of signs and symptoms of clinical improvement: being 
taken up and transported by dendritic cells, the self-
epitope would likely interact directly with the antigen 
binding site of anti-idiotypic T cells on the cellular mem-
brane (paratope), thus activating an immunoregulatory 
response. The idiotype-anti-idiotype network on the cell 
membrane is considered central in immunoregulation 
involving auto antigens. Therefore, the peptide would not 
interact with autoreactive T lymphocytes and thus would 
bypass the most detrimental component of the immune 
response in patients with arthritis. In fact, pro-inflam-
matory responses have never been observed in  vivo or 
in vitro.
We hypothesized that the intrasynovial Rifamycin SV 
[1, 2], through these autonomic immunological mecha-
nisms established an endogenous immunotherapy.
The PBMCs from RA patients, in baseline cultures, 
were unresponsive to synthetic HSP60 bystander pep-
tide P1 (Fig.  1) but exhibited an immune response to 
the addition of the ultra filtrate UF-sf which was char-
acterized by significant increase in the expression of 
CTLA-4 by CD4+CD25+ (p  =  0.05) and an equally 
significant reduction of CD69 (p = 0.04); modifications 
which jointly imply an immunoregulatory response 
that only a specific antigen is able to elicit in subjects 
that have, in all probability, a basic immunological 
trend potentially oriented toward immunoregulatory 
responses.
In this context, a certain role might be played by the 
innate immunity that is persistently activated in patients 
with RA [36, 37].
The addition of autologous UF-f/t to PBMCs cultured 
from vaccinated patients elicited minimal change in cel-
lular markers (Table  2). This might indicate that mono-
nuclear cells are functionally impaired by previous 
in vivo stimulation. In contrast, in cultures from normal 
subjects there was a marked reduction in the expres-
sion of CTLA-4 (−33 %) after the addition of autologous 
ultrafiltrate (Table  2). This finding reinforces the specu-
lation that subjects with RA have a particular arthritic 
immunological profile, particularly earliness of clinical 
improvement and the duration of a single subcutaneous 
injection.
As regards the immune response in rats with ongo-
ing arthritis, the mechanisms of protection might be the 
same with the difference that, being induced, the disease 
is self-limiting.
However, the epitope injected with human ultra filtrate, 
very likely related to HSP60 molecule, remains unknown. 
As the HSP is an extraordinarily evolutionarily conserved 
molecule the presence of its epitopes in the endocytic 
compartment of human cells is almost obviously. It is 
well known that T cells specific for self-Hsp even exist in 
the normal T cell repertoire.
Immune response to hsp60 by rheumatoid synovial 
cells and the presence of these antigens in inflamed joints 
and subcutaneous nodules of RA patients were reported 
[38, 39]. In JCA this responsiveness was directed to self 
hsp60 and the increased response of Hsp60-specific 
Page 10 of 12Caruso et al. J Transl Med  (2016) 14:162 
T-cells correlated with the spontaneous disease remis-
sion [40].
Notably, the epitopes contained in our ultrafiltrates 
and responsible for the prevention of AA, appear to be 
smaller than the aa sequence 180–188 of the mycobacte-
rial HSP65 which, while preventing the AA and despite 
having therapeutic effects on this experimental model, 
is not considered as the pathogenic autoantigen (it is not 
able to induce the disease) [41].
The auto antigens extracted here, can be enriched many 
times (w/v), along with all the other small molecules, by 
aggregating multiple ultrafiltrates and subjecting them to 
lyophilization. Thus prepared, the ultrafiltrate might also 
be autologously used in non-rheumatological autoimmune 
disease, particularly in cases where the number of APCs 
in the blood is low, even if the autoantigen is unknown 
(personal obs). An adverse reaction to these antigens is 
unlikely given that peripheral lymphocytes reactive to self 
peptides are eliminated in the ontogenic selection.
In summary, this study outlines the unusual properties 
of the unknown and very probably pathogenic peptide 
that is contained in the ultrafiltrates prepared from rheu-
matoid PBMCs and synovial fluid. However, at the same 
time, the positive responses following subcutaneous 
administration of ultrafiltrates highlights the immuno-
logical profile of patients with RA, characterized by the 
potential capacity to reactivate, as a result of a specific 
stimulus, a pre-existing protective mechanism that is, of 
itself, insufficient to produce clinically significant effects.
The same human ultra filtrates contain an epitope, 
related to the molecule HSP60, that is able to modulate 
the immune mechanism implicated in AA and to stimu-
late protective immunity.
These studies should be considered very preliminary, 
and the clinical data must be interpreted with caution in 
view of the small number of cases.
No side effects were observed in our study follow-
ing patient treatments, including at the site of subcuta-
neous administration of UF-sf or UF-f/t. However, on 
occasion the beneficial response was preceded by slight 
exacerbation of symptoms. Two patients in group UF-R 
experienced a hypersensitivity reaction after the second 
injection; both were characterized by skin eruptions that 
regressed spontaneously in a few days. In 13 patients, 
the intradermal sensitivity test to Rifamycin SV prior to 
enrollment was considered positive (appearance of wheal 
≥0.5 cm). None of our patients experienced side effects 
common to immunotherapies in humans and in most 
studied experimental models of autoimmune diseases 
such as diabetes and multiple sclerosis (hypersensitivity 
reactions, immunization towards cryptic epitopes, or de 
novo induction of autoimmune diseases).
Conclusions
  – The disruption of PBMCs by the lytic action of Rifamy-
cin or by freeze/thawing in vitro, caused the release of 
endosomal content and pathogenic autoantigens from 
APCs present in the circulation, which were then be 
isolated from degrading enzymes and bound immuno-
logic molecules by ultrafiltration.
  – The method of recovery, which utilize an ultrafilter 
with a cut-off of 10  kDa, lead to the conclusion that 
the possible pathogenic peptide is not associated with 
HLA-DR molecules.
  – We prepared four different ultrafiltrates, two of which 
were derived from the breakdown of PBMCs, one 
from the supernatant of PBMCs cultures and one from 
synovial fluid. Three of these were utilized in trials of 
autologous immunotherapy by injecting them subcuta-
neously in 115 patients with early RA (disease duration 
of less than 12 months).
  – At clinical monitoring on the 30th  day, 22/58 (38  %) 
patients treated with the autologous ultrafiltrate pre-
pared by the freeze/thawing of PBMCs reached an 
ACR20. But in some patients these effects occurred 
early, sometimes after a week.
  – The status of the auto antigen in the ultrafiltrate, i.e., a 
peptidic fragment, not associated with a class II MHC 
molecule, likely taken up and transported by dendritic 
cells, allows the administered pathogenic peptide to 
by-pass an interaction with autoreactive T cells and 
favor interaction with the anti-idiotype (paratope) 
antigen binding sites, activating an immunoregulatory 
response. The early appearance of clinical improve-
ment in the patients might be related to this mecha-
nism of response.
  – Examining the results obtained in rats with AA and in 
subjects with RA it is reasonable to assume there are 
at least two unknown immunoactive epitopes: one, 
derived from the molecule of HSP60 (HSP is highly 
evolutionarily conserved molecule), which causes 
immunosuppression in rats, the other develops its 
immunotherapeutic capacity in RA patients. They are 
both present in humans.
  – In vitro studies defined certain notable immunomodu-
latory properties of the ultrafiltrates, and thus of the 
peptide, and outlined a particular immunological pro-
file of the subjects with RA.
  – During the course of the immunotherapy with freeze/
thaw and acellular synovial fluid ultra filtrates, no side 
effects of any type were observed, nor were hypersen-
sitivity or anaphylactic reactions induced. Adjuvant of 
any sort was never used. However, two subjects treated 
with ultrafiltrate prepared with Rifamycin SV experi-
enced a morbilliform rash.
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Perspectives
In agreement with the preliminary results and consider-
ing the huge amount of knowledge in the field of human 
immunotherapy and in the prevention of experimental 
autoimmune diseases, we suggest that the use of ultrafil-
trates, with the appropriate adjustment of the scheme, be 
applied for a perspective clinical study aimed at prevent-
ing the appearance of RA in subjects with a genetic profile 
associated with elevated risk for RA and/or a high level 
of anti-citrullinated protein antibodies. Furthermore, as 
autoantigen(s) can be enriched many times (w/v) through 
aggregation of multiple ultrafiltrates followed by lyophili-
zation (Caruso unpublished), this method might also be 
applied in non-rheumatological autoimmune disease, par-
ticularly where the number of APCs in the blood is low
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